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mTORC2-PKBa/Akt1 Serine 473 Phosphorylation
Axis Is Essential for Regulation of FOXP3 Stability
by Chemokine CCL3 in Psoriasis
Ling Chen1, Jinjin Wu1, Eric Pier2, Yun Zhao3 and Zhu Shen4
The connection between infections and acute guttate psoriasis (AGP) outbreaks/chronic plaque psoriasis (CPP)
exacerbation has been known for years. Impaired function of FOXP3þ Tregs in psoriasis has been identified.
However, the mechanisms behind these two observations have not been fully interpreted. In the present study, we
provide evidence to support chemokine CCL3 as one of the vital links between infections and FOXP3 stability in
the psoriatic microenvironment. We found that serum CCL3, strongly induced by microorganism infections
including streptococcus, was closely correlated with FOXP3 levels in CD4þCD25þ T cells of patients with
psoriasis. CCL3 manipulated FOXP3 stability in a concentration-dependent bidirectional manner. High-concentra-
tion CCL3 decreased FOXP3 stability by promoting FOXP3’s degradation through K48-linkage ubiquitination. This
degradation was mainly dependent on upregulation of Serine 473 phosphorylation of the PKBa/Akt1 isoform, and
almost independent of mTORC1 (mammalian target of rapamycin complex 1) activity. On the other hand, low-
concentration CCL3 could enhance FOXP3 stability by the maintenance of the PKC pathway and the restriction of
the PKB/Akt pathway. We further demonstrated that enhancing FOXP3 stability by low-concentration CCL3
attributed, at least partly, to the prevention of cytoplasmic Sin1, a vital component of mTORC2, nuclear
translocation. Our results suggest vital roles for CCL3-mTORC2-isoform PKB/Akt1 S473 phosphorylation axis in
FOXP3þ Tregs and the development of psoriasis.
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INTRODUCTION
Psoriasis is one of the most common immune-mediated
autoinflammatory diseases under certain genetic predisposi-
tions and environmental stresses (e.g. infections) (Nestle et al.,
2009). Acute guttate psoriasis (AGP) and chronic plaque
psoriasis (CPP) are two common types of psoriasis. The
sudden appearance of AGP may be either the first
manifestation of psoriasis in a previously unaffected person
or an acute exacerbation of CPP. The trigger to AGP is strongly
associated with throat streptococcal infection or some other
type of infection preceding the outbreak, with reported
incidence ranging between 56 and 97% (Prinz, 2001;
Valdimarsson et al., 2009).
FOXP3, forkhead/winged helix transcription factor 3, is a
master transcription factor for the development and function
of FOXP3þ Tregs (regulatory T cells) (Shen et al., 2009).
Recent evidence from our own and other groups suggested
that impaired function of FOXP3þTregs leads to the over-
activation of effector cells, which is believed to play important
roles in psoriasis development (Sugiyama et al., 2005; Chen
et al., 2008; Bovenschen et al., 2011). For more than a
decade, FOXP3þTregs have been put at the center of immu-
nological investigation, and several human trials have been
initiated. But recent research found that the stability of FOXP3
could wax and wane and it was not as stable as has been
thought (Gadina and O’Shea, 2009; Zhou et al., 2009). Under
proinflammatory conditions of exacerbated psoriasis, FOXP3þ
Tregs could readily differentiate into Th17 cells (Bovenschen
et al., 2011; Lin et al., 2011; Soler and McCormick, 2011).
Th17 cells are an inflammation-associated subpopulation of
T cells and they are the opposite side to Tregs.
The connection between infections and the AGP outbreaks/
CPP exacerbation has been known for years, but the exact
mechanism by which the infection triggers the lesions is not
fully understood. Likewise, although impaired function of
FOXP3þ Tregs in psoriasis was identified, the mechanism
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behind this not been fully interpreted. Based on the above
background, we were curious whether FOXP3 protein stability
is affected by infections and the chemokines they promoted.
In the present study, we found that chemokine (C-C motif)
ligand 3 (CCL3), strongly induced by microorganism infec-
tions including streptococcus (Mitsui et al., 2002), was closely
correlated with FOXP3 protein levels in CD4þCD25þ T cells
of patients with psoriasis. We provide evidence that CCL3
manipulated FOXP3 protein stability by posttranslational
modification through the CCL3-mTORC2-isoform PKBa/Akt1
S473 phosphorylation axis. Our results suggest vital roles for
this axis in FOXP3þ Tregs and the development of psoriasis.
RESULTS
Serum CCL3 concentration showed an inverse correlation with
FOXP3 protein levels in CD4þCD25þ T cells of patients with
psoriasis
We found that there were higher serum CCL3 and lower
FOXP3 protein in CD4þCD25þT cells in AGP than in CPP
(Figure 1a). Within AGP, there was an inverse correlation
between serum CCL3 and FOXP3 protein levels (Figure 1b).
AGP patients with more lesions (Supplementary Table online)
showed higher serum CCL3 compared with those with fewer
lesions. By contrast, FOXP3 levels were lower in patients with
more lesions than in those with fewer lesions (Figure 1c). Next
we compared the dynamic changes of serum CCL3 and
FOXP3 levels in CD4þCD25þT cells after two-month
follow-up for these 11 AGP patients. We found that, among
them, the lesions of five patients improved significantly when
return-visiting. Remarkably lower serum CCL3 and more
FOXP3 protein was observed for these patients when
return-visiting two months later, compared with their first visit
(Figure 1d). The lesions of three AGP patients remained
strikingly refractory when return-visiting two months later.
There were no obvious changes for their serum CCL3 and
FOXP3 levels before and after treatment (Figure 1e). Two of
the AGP patients developed CPP (Figure 1f) and only one
accepted the examination of skin biopsy when both first and
return-visiting (Figure 1g and h). It was shown that the infiltrate
of neutrophils was reduced when AGP (Figure 1g) developed
into CPP (Figure 1h). Conversely, FOXP3þ infiltration was
increased during this transition. These above results demon-
strated an inverse correlation between serum CCL3 and
FOXP3 levels of CD4þCD25þT cells in psoriasis.
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Figure 1. Serum CCL3 concentration showed an inverse correlation with FOXP3 protein level in CD4þCD25þ T cells of psoriasis. (a) Serum CCL3 and FOXP3
levels of CD4þCD25þ T cells in acute guttate psoriasis (AGP; n¼11) and chronic plaque psoriasis (CPP; n¼15) were measured by ELISA and western blot
respectively (*t0 ¼ 6.575, Po0.001; **t¼13.0911, Po0.0001). (b) Within AGP, there was a negative correlation between serum CCL3 and FOXP3 protein levels
(Spearman correlation coefficient¼  0.791, P¼0.004). (c) Serum CCL3 and FOXP3 levels of CD4þCD25þ T cells in AGP with more lesions (no less than the
mean number of 42 totally, n¼6, Supplementary Table online) and those of fewer lesions (n¼ 5) were measured by ELISA and western blot respectively
(*t¼ 2.6725, P¼0.0255, **t¼ 6.781, P¼ 0.0001). (d) Lesions on five patients of AGP improved significantly at their return visit two months later. Serum CCL3 and
FOXP3 levels of CD4þCD25þ T cells in these patients before and after treatment were measured by ELISA and western blot respectively (*t¼6.7665, P¼0.0001;
**t0 ¼5.8995, Po0.01). (e) Three patients of AGP remained strikingly refractory lesions two months later. Serum CCL3 and FOXP3 levels of CD4þCD25þ T cells
in these patients before and after treatment were measured by ELISA and western blot respectively (*t¼ 0.4777, P¼ 0.6578; **t¼0.0229, Po0.9828).(f) Two of the
patients of AGP developed into CPP when return-visiting. (g and h) Panels (g) and (h) show the histopathological changes (a single patient) when AGP (g)
developed into CPP (h)—reduced neutrophil granulocyte (green arrows) and increased FOXP3þ infiltration in the papillary layer (yellow arrows). Scale
bar¼ 20mm.
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High-concentration CCL3 promoted the degradation of nuclear
FOXP3 protein by proteasome pathway through K48-linkage
ubiquitination
We tried to demonstrate the negative impact of CCL3 on
FOXP3 based on the above observations. We found that
addition of CCL3 decreased FOXP3 levels remarkably in
isolated CD4þCD25þ T cells (Figure 2a). The antagonism
by Maraviroc binding to CCR5 (one of receptors for CCL3)
partly rescued FOXP3 levels in these cells (Figure 2a). This
rescue result further confirmed the negative impact of CCL3
on FOXP3.
In order to explore whether this negative impact occurred
on the protein level and the mechanism behind it, we
established CCR5/FOXP3-GFP(no sorting) cells (Supplementary
Material online). We found that CCL3 significantly attenuated
the GFP-positive percentage as early as 1-hour incubation
with CCL3 (Figure 2b), which suggested this attenuating most
likely occurred on the FOXP3 protein level. We further
confirmed this suggestion by cycloheximide chase assay, in
which CCL3 significantly decreased FOXP3 protein half-life,
compared with blank medium (Figure 2c).
FOXP3 has been proven to be an unstable nuclear tran-
scription factor (Zhou et al., 2009; Chen et al., 2011). So next,
we wanted to further confirm the attenuation of FOXP3
protein by CCL3 was reached through reducing FOXP3
stability. Firstly we found that MG132, a proteasome
Maraviroc
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Figure 2. CCL3 promoted the degradation of FOXP3 protein by proteasome pathway through K48-linkage ubiquitination. (a) CD4þCD25þ T cells were
isolated and starved for 6 h (n¼ 4). They were then stimulated by CCL3 with or without the pretreatment of Maraviroc (200 ng/ml, CCR5 antagonist, a gift from
Prof. Joseph G. Sodroski, Harvard Medical School) for 2 h. CCL3 decreased FOXP3 level and Maraviroc partly rescued FOXP3 measured by western blot
(*t¼ 7.0145, P¼ 0.0004, **t¼ 3.7492, P¼ 0.0095). (b) After starvation overnight, CCR5/FOXP3-GFP(no sorting) cells (n¼ 3, Supplementary Material online) were
stimulated with or without CCL3 (100 ng/ml) for 1 h. CCL3 significantly attenuated the GFP-positive percentage measured by FACS (*t¼ 6.4946, P¼0.0029).
The control is for zero points as a negative control. (c) Starved CCR5/FOXP3 cells were chased by cycloheximide for indicated time. FOXP3 protein was
immunoprecipitated with anti-HA antibody and analyzed by western blot with anti-FOXP3 antibody. CCL3 significantly decreased FOXP3 protein half-life
(*t¼ 5.0351, P¼ 0.0073. (d) CCR5/FOXP3 cells were treated by CCL3 (100 ng/ml) for two hours with or without MG132 (50mM). MG132 rescued the attenuation of
FOXP3 protein by CCL3 analyzed with western blot. (e) CCR5/FOXP3 cells were treated with CCL3 (100 ng/ml) after starvation overnight. CCL3 enhanced nuclear
FOXP3 ubiquitination measured by immunoprecipitation and western blot. (f) CCR5/Ub/FOXP3 and CCR5/Ub-K48R/FOXP3 cells were treated and checked the
ubiquitination levels of nuclear FOXP3 by immunoprecipitation and western blot as above. K48R almost abolished FOXP3 ubiquitination, acompanied with
increased FOXP3 protein level. One representative experiment of three is shown in panels c–f. *Isotype IgG for immunoprecipitation in (e) and (f).
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pathway inhibitor, could rescue the attenuation of FOXP3
protein by CCL3, suggesting the role of the proteasome
pathway in decreasing FOXP3 stability (Figure 2d). We next
found that CCL3 remarkably attenuated nuclear FOXP3
protein levels in CCR5/FOXP3 cells by enhancing its
ubiquitination reaction (Figure 2e). Ubiquitin lysine48
(K48)-linkage ubiquitination reaction has been implicated in
a wide range of protein degradation via the proteasome
pathway. By comparing CCR5/Ub/FOXP3 and CCR5/Ub-
K48R/FOXP3 cells, we found that the ubiquitin mutant
of K48R almost abolished the ubiquitination of nuclear
FOXP3, accompanied by increased FOXP3 protein levels
(Figure 2f). Our data demonstrated that CCL3 promoted the
degradation of nuclear FOXP3 protein by the proteasome
pathway through K48-linkage ubiquitination.
Degradation of FOXP3 promoted by high-concentration CCL3
depended on its activation of PKB/Akt pathway
The PKB/Akt signaling pathway is one of the main down-
stream targets of CCL3 stimulation (Lentzsch et al., 2003). We
investigated whether the degradation of FOXP3 promoted by
CCL3 depended on its activation on the PKB/Akt pathway.
We found that MK2206 significantly increased the GFP-
positive percentage in CCR5/FOXP3-GFP(no sorting) cells
(Figure 3a). This suggested that inhibition of the PKB/Akt
pathway could increase FOXP3 stability. Next, MK2206
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Figure 3. Degradation of FOXP3 promoted by CCL3 depended on its activation of PKB/Akt pathway and PKBa/Akt1 was the main isoform responsible for the
degradation of FOXP3 by CCL3. (a) CCR5/FOXP3-GFP(no sorting) cells (n¼ 3, Supplementary Material online) were stimulated by CCL3 for 30 min and then
co-treated with MK2206 (1mM, PKB/Akt pathway inhibitor) or DMSO for 2 h. MK2206 significantly increased the GFP-positive percentage measured by FACS
(t¼ 9.0544, P¼0.0008). The control is for zero points as a negative control. (b) CCR5/FOXP3 cells were stimulated with CCL3 and MK2206 as above. MK2206
remarkably increased nuclear FOXP3 by attenuating its ubiquitination measured by western blot and immunoprecipitation. (c) CCR5/FOXP3 were stimulated by
CCL3 for 30 min and then co-treated with MK2206 of various concentrations for 2 h. FOXP3 and phosphorylation of PKB/Akt at Ser473 were assessed by western
blot. (d) CCR5/FOXP3 were stimulated by CCL3 for 30 min and then co-treated with MK2206 (1mM) for indicated hours. FOXP3 and phosphorylation of PKB/Akt at
Ser473 were assessed by western blot. (e) Akt1/CCR5/FOXP3, Akt2/CCR5/FOXP3, Akt3/CCR5/FOXP3 cells and (f) CCR5/shRNA-PKBa/Akt1/FOXP3 and CCR5/
pLKO.1/FOXP3 cells were treated with CCL3 (100 ng/ml) for 2 h after starvation overnight. Compared with other isoforms, PKBa/Akt1 isoform decreased nuclear
FOXP3 level by increasing its ubiquitination. shRNA for PKBa/Akt1 successfully rescued FOXP3 level. One representative experiment of three is shown for
(b, c, d, e, and f). *Isotype IgG for immunoprecipitation.
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remarkably increased nuclear FOXP3 protein levels in
CCR5/FOXP3 cells by attenuating FOXP3’s ubiquitination
(Figure 3b). This result further confirmed the enhancement of
FOXP3 stability by PKB/Akt inhibition. Next we demonstrated
that MK2206 maintained FOXP3 stability in a concentration-
dependent and time-dependent manner (Figure 3c and d). The
rapid rescue of FOXP3 protein (at 0.5 h, Figure 3d) by MK2206
and the deficiency of transcription elements on the promoter
of exogenous HA-FOXP3 plasmid further confirmed that the
attenuating of FOXP3 occurred on the protein level. These
data also demonstrated that the degradation of FOXP3
promoted by CCL3 depended on its activation on the PKB/
Akt pathway and inhibition of this pathway by MK2206 could
reverse the degradation of FOXP3 by attenuating its
ubiquitionation.
PKBa/Akt1 was the main isoform responsible for the degradation
of FOXP3 by CCL3
Studies have revealed different functional roles of PKB/Akt
isoforms and that isoform-specific signaling contributes to the
diversity of PKB/Akt activities (Gonzalez and McGraw, 2009).
We aimed to identify the isoform(s) that undertook the main
responsibility for the degradation of FOXP3 by high-concen-
tration CCL3. Akt1/CCR5/FOXP3, Akt2/CCR5/FOXP3 and
Akt3/CCR5/FOXP3 cells were built based on lung fibroblast
cells from Akt1fl/flAkt2-/-Akt3-/- mice (Supplementary Material
online). By checking the total FOXP3 level and its ubiquitina-
tion, we found that PKBa/Akt1 significantly decreased nuclear
FOXP3 level by increasing the ubiquitination of FOXP3,
compared with the other two isoforms (Figure 3e). This result
was further confirmed by using CCR5/pLKO.1/FOXP3 and
CCR5/shRNA-PKBa/Akt1/FOXP3 cells, in which shRNA for
PKBa/Akt1 successfully rescued FOXP3 levels (Figure 3f). These
data demonstrated that PKBa/Akt1 was the main isoform of
PKB/Akt responsible for the degradation of FOXP3 by CCL3.
Serine 473 phosphorylation of PKBa/Akt1 was required for the
degradation of FOXP3 by CCL3 and the mTORC1 pathway was
not the main mediator for this degradation
PKB/Akt activation requires phosphorylation at two sites,
threonine 308 (T308) and serine 473 (S473). In order to
determine whether the phosphorylation at both these sites was
required for the degradation of FOXP3, Akt1-wt/CCR5/FOXP3,
Akt1-S473A/CCR5/FOXP3 and Akt1-T308A/CCR5/FOXP3
cells were treated with CCL3 (100 ng/ml) for 2 h after starva-
tion overnight. Compared with the wt and T308A mutant,
Akt1-S473A significantly increased nuclear FOXP3 level by
decreasing the ubiquitination of FOXP3 (Figure 4a). This
suggested that S473 phosphorylation of PKBa/Akt1 is required
for the degradation of FOXP3 by high-concentration CCL3.
The result in Figure 4b showed that high-concentration CCL3
had no significant impact on the phosphorylation of 4E-BP1,
one of the well-characterized substrates of mTORC1. In
addition, rapamycin, even at high concentrations (100 nM),
failed to rescue the degradation of FOXP3 by CCL3
(Figure 4b). This suggested that the mTORC1 pathway was
not the main mediator for the degradation of FOXP3 promoted
by high-concentration CCL3.
Sin1, an essential mTORC2 component, played a vital role in the
degradation of FOXP3 via activation of S473 phosphorylation of
PKBa/Akt1 by CCL3
mTORC2 functionally acts as the main kinase complex for
phosphorylating PKB/Akt at S473. So we postulated that
mTORC2 might play important roles in the degradation of
FOXP3 via activation of PKB/Akt pathway by CCL3. In order
to confirm this hypothesis, we established Akt1/CCR5/pBabe/
FOXP3 and Akt1/CCR5/Sin1/FOXP3 cells. We found exogen-
ous overexpression of Sin1 reduced the stability of FOXP3 by
increasing S473 phosphorylation levels and FOXP3’s ubiqui-
tination (Figure 4c). In Akt1/CCR5/shRNA-Sin1/FOXP3 cells,
knockdown of Sin1 by shRNA protected nuclear FOXP3 from
degradation by almost abolishing S473 phosphorylation and
decreasing FOXP3’s ubiquitination (Figure 4d). These data
demonstrated that Sin1, functioning as an essential mTORC2
component, played a vital role in the degradation of FOXP3
via activation of S473 phosphorylation of PKBa/Akt1 by CCL3.
Serum CCL3 showed positive correlation with pAkt(S473) levels,
while pAkt(S473) levels showed inverse correlation with FOXP3
protein level in CD4þCD25þ T cells of psoriasis
In order to confirm the above results from stable cell lines, we
checked the relationship between serum CCL3 and pAkt(S473)
levels, pAkt(S473) and FOXP3 protein levels in CD4þ
CD25þT cells of patients with psoriasis. We found a positive
correlation between serum CCL3 and relative pAkt(S473)
levels, an inverse correlation between pAkt(S473) and FOXP3
protein levels in CD4þCD25þT cells of AGP (Figure 4f
and g). These relationships were further confirmed by compar-
ing the serum CCL3, pAkt(S473) and FOXP3 levels in CD4þ
CD25þT cells of AGP and CPP (Figure 1a and e), in patients
with fewer and more guttate lesions (Figures 1c and 4h), in
improved psoriatic patients before and after treatment (Figures
1d and 4i), and in refractory psoriatic patients before and after
treatment (Figures 1e and 4j).
Concentration-dependent bidirectional regulation of FOXP3
stability by CCL3
In order to identify the minimum concentration of CCL3
capable of degradating FOXP3, we treated isolated CD4þ
CD25þT cells with CCL3 at various concentrations after
starvation. We unexpectedly found that the impact of CCL3 on
FOXP3 stability was suggested to be bidirectional. CCL3 of
high concentration remarkably decreased FOXP3 stability. On
the contrary, CCL3 of low concentration stabilized FOXP3,
compared with blank medium (Supplementary Figure S1
online). CCL3 of low concentration maintained FOXP3 levels
by decreasing the ubiquitination of nuclear FOXP3 in CCR5/
FOXP3 cells (Figure 5a). These data suggested the concentra-
tion-dependent bidirectional regulation of FOXP3 protein
stability by CCL3.
Maintenance of FOXP3 stability by low-concentration CCL3
required PKC pathway and restrained S473 phosphorylation of
PKB/Akt pathway
We examined the alteration of signaling pathways behind
the maintenance of FOXP3 stability by low-concentration
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CCL3. We found that inhibition of the PKC pathway by
Ro-31-8220 (a selective PKC inhibitor) impaired the
stability of FOXP3, leading to lower FOXP3 protein
(Figure 5b). This suggested that a certain magnitude of PKC
signal was required for the maintenance of FOXP3 stability by
low-concentration CCL3. This was further supported by the
result shown in Figure 5c, in which activation of the PKC
pathway by PMA (a selective PKC activator) reinforced the
stability of FOXP3.
Next, we found that S473 phosphorylation of the
PKB/Akt pathway was restrained under the stimulation of low-
concentration CCL3 (Figure 5d). In myristoylated-Akt1 cells
where S473 phosphorylation of the PKB/Akt pathway
was constitutively active (Supplementary Material online),
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Figure 4. Serine 473 phosphorylation of PKB/Akt1 was required for the degradation of FOXP3 by CCL3. Sin1, an essential mTORC2 component, played a vital
role in this degradation. (a) Akt1-wt/CCR5/FOXP3, Akt1-S473A/CCR5/FOXP3, and Akt1-T308A/CCR5/FOXP3 cells; (c) Akt1/CCR5/pBabe/FOXP3 and Akt1/CCR5/
Sin1/FOXP3 cells; (d) Akt1/CCR5/pLKO.1/FOXP3 and Akt1/CCR5/shRNA-Sin1/FOXP3 cells (Supplementary Material online). Cells in a, c, and d were treated with
CCL3 (100 ng/ml) for 2 h after starvation overnight. S473 phosphorylation of PKBa/Akt1 is required for the degradation of FOXP3 by high-concentration CCL3 (a).
Sin1, an essential mTORC2 component, played a vital role in the degradation of FOXP3 via activation of S473 phosphorylation of PKBa/Akt1 by CCL3
(c, d). One representative experiment of three is shown. *Isotype IgG for immunoprecipitation. (b) CCR5/FOXP3 were stimulated by CCL3 for 30 min and then co-
treated with or without rapamycin (100 nM) for 2 h. CCL3 had no significant impacts on the phosphorylation of 4E-BP1, one of the well-characterized substrates of
mTORC1. Rapamycin with high concentration (100 nM) still failed to rescue the degradation of FOXP3. (e) The relative pAkt(S473) level in CD4þCD25þT cells
from AGP (n¼ 11) was higher than that in chronic plaque psoriasis (n¼ 15, *t¼8.9227, Po0.0001). These protein samples were as same as those in Figures 1a.
(f) The positive correlation between serum CCL3 and relative pAkt(S473) levels in CD4þCD25þT cells from AGP (n¼11, Spearman correlation
coefficient¼ 0.736, P¼ 0.01). (g) The inverse correlation between relative pAkt(S473) levels and relative FOXP3 in CD4þCD25þ T cells from AGP (n¼ 11,
Spearman correlation coefficient¼ 0.700, P¼ 0.016). (h) The relative pAkt(S473) level in CD4þCD25þ T cells from AGP with less lesions (n¼ 5) was lower
than that with more lesions (n¼6, *t¼2.705, Po0.0242). These protein samples were as same as those in Figure 1c. (i) Five patients of AGP improved two months
later. The relative pAkt(S473) level in CD4þCD25þT cells of these patients when first-visiting was higher than that of two-month later (*t¼ 9.283, Po0.0001).
These protein samples were as same as those in Figure 1d. (j) Three patients of AGP remained refractory lesions two months later. The relative pAkt(S473) level in
CD4þCD25þT cells of these patients when first visiting was not changed significantly, compared with that of two-months later (*t¼ 0.1305, P¼ 0.9025).
These protein samples were as same as those in Figure 1e.
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low-concentration CCL3 cannot restrain the PKB/Akt activa-
tion, leading to its failure to increase FOXP3 protein (Figure 5e).
In isolated CD4þCD25þT cells stimulated by low-concentra-
tion CCL3, further inhibition of already-restrained S473 phos-
phorylation with MK2206 failed to increase FOXP3 protein
level significantly (Figure 5f). In addition, activation of S473
phosphorylation of PKB/Akt pathway by IGF-1 could impair
FOXP3 stability maintained by low-concentration CCL3
(Figure 5g). Collectively, these data demonstrated that main-
tenance of FOXP3 stability by low-concentration CCL3 required
the maintenance of the PKC pathway and the restriction of
S473 phosphorylation of the PKB/Akt pathway. It was also
suggested that there should be some cross-talk between the
PKC and PKB/Akt pathways concerning the regulation of
FOXP3 stability.
Enhancing FOXP3 stability by low-concentration CCL3
attributed, at least partly, to the prevention of cytoplasmic Sin1
nuclear translocation by PKC pathway
In the above study, some cross-talk between PKC and PKB/Akt
pathways concerning the regulation of FOXP3 stability was
suggested. We have demonstrated Sin1, an essential mTORC2
component, played a vital role in the degradation of FOXP3
via activation of the PKB/Akt pathway by CCL3 of high
concentration. In this section, we tried to find out whether
Sin1 performed the cross-talk between the PKC and PKB/Akt
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Figure 5. Maintenance of FOXP3 stability by low-concentration CCL3 required PKC pathway and restrained S473 phosphorylation of PKB/Akt pathway.
(a) CCR5/FOXP3 cells were treated with CCL3 of 0.5 ng/ml after starvation overnight. CCL3 stabilized nuclear FOXP3 level by decreasing the ubiquitination
of FOXP3. One representative experiment of three is shown. *Isotype IgG for immunoprecipitation. (b) CD4þCD25þ T cells were treated with Ro-31-8220
(10mM, selective PKC inhibitor) or DMSO for 15 min after pretreatment of CCL3 (0.5ng/ml) for 2 h (n¼4). Ro-31-8220 treatment impaired the stability of FOXP3
(*t¼ 4.5471, P¼ 0.0039). (c) CD4þCD25þ T cells were treated with PMA (100 ng/ml, selective PKC activator) or DMSO for 1.5 h (n¼4). Activation of PKC
pathway by PMA reinforced the stability of FOXP3 (*t0 ¼ 5.0791, Po0.05). (d) Akt1/CCR5/FOXP3 and (e) myr- Akt1/CCR5/FOXP3 cells were treated with CCL3
(0.5ng/ml) for 2 h respectively. S473 phosphorylation was restrained under the stimulation of low-concentration CCL3. Disability to restrain the PKB/Akt activation
in myristoylated-Akt1 cells failed to increase FOXP3 protein by CCL3. One representative experiment of three is shown. (f) CD4þCD25þ T cells were co-treated
with CCL3 (0.5 ng/ml) and MK2206 (1mM, PKB/Akt inhibitor) or DMSO for 2 h (n¼4). Further inhibition of already-restrained S473 phosphorylation with MK2206
failed to increase FOXP3 protein (*t0 ¼ 0.7937, P40.05). (g) CD4þCD25þ T cells were treated with or without IGF-1 (100 ng/ml) for 15 min after pretreatment
of CCL3 (0.5ng/ml) for 2 h (n¼ 4). Activation of S473 phosphorylation by IGF-1 impaired FOXP3 stability maintained by low-concentration CCL3 (*t¼ 4.625,
P¼ 0.0036).
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pathways concerning the regulation of FOXP3 stability. Here
we provide evidence that cytoplasmic Sin1 translocated into
nuclei under the condition of a decreased PKC pathway caused
by Ro-31-8220 in CCR5/Sin1/FOXP3 cells (Figure 6). This
nuclear translocation of Sin1 led to increased nuclear PKB/Akt
phosphorylation (S473) and decreased nuclear FOXP3 levels
(Figure 6a). The attenuated FOXP3 level occurred mainly on
the protein level, because the mRNA levels of FOXP3 were
not decreased during Ro-31-8220 treatment (Supplementary
Figure S2 online). Based on these results, we suggested that
manipulation of cytoplasmic-nuclear translocation of Sin1 by
the PKC pathway was one of the cross-talks with the PKB/Akt
pathway concerning FOXP3 stability. These data demon-
strated that enhancing FOXP3 stability by low-concentration
CCL3 attributed, at least partly, to the prevention of cytoplas-
mic Sin1 nuclear translocation by the PKC pathway.
DISCUSSION
Chemokine CCL3 plays important roles in regulating T cell-
mediated immunity for host defense against microorganism
infection (Olszewski et al., 2000). It evolved to benefit the
host, but inappropriate utilization can cause many diseases,
e.g. multiple sclerosis (Szczucin´ski and Losy, 2007),
rheumatoid arthritis (Iwamoto et al., 2008), and psoriatic
arthritis (Szodoray et al., 2007). In this study we observed
and demonstrated the inverse correlation between high-
concentration serum CCL3 and FOXP3 protein levels in
psoriasis. In accordance with our results, published studies
showed that Evasin-1, one of the CCL3’s neutralization
proteins from ticks (bloodsucking parasites), reduced
symptoms in a murine model of skin inflammation that
resembles psoriasis in humans (De´ruaz et al., 2008).
Moreover, it has been demonstrated that there was cross-talk
between the function of CCL3 and IFN-gamma (Dorner et al.,
2002), a cytokine and its pathway known in the development
of psoriasis (Kryczek et al., 2008).
CCR5 is one of the receptor for CCL3 and has been shown
to be involved in the pathogenesis of inflammation and
autoimmune disorders, including psoriasis (Ariel et al., 2006;
Gros et al., 2009). We showed that Maraviroc, CCR5’s anta-
gonist, could rescue FOXP3, which supported the negative
impact of CCR5 signal on FOXP3. However, according to
Yurchenko et al. (2006), CD4þCD25þ Tregs, compared
with normal CD4þ T cells, preferentially expressed CCR5.
We think the reason for these ‘‘paradoxical’’ observations is
likely that the high level of CCR5 may facilitate Treg cells to
migrate in response to CCR5 ligands and keep the balance
between Tregs and effectors in infection sites. This also
suggests the diversity of CCR5 signaling autoimmune and
infection.
FOXP3 protein has been demonstrated to become more
stable when it was acetylated, and hyperacetylation of FOXP3
could prevent its polyubiquitination and subsequent protea-
somal degradation (van Loosdregt et al., 2010; Zhang et al.,
2012). Our results suggested that CCL3 might have some effect
on FOXP3’s acetylation, which requires further investigation.
We failed to observe this concentration-dependent
bidirectional attribute of CCL3 in Figure 1b because the
lowest CCL3 of AGP patients in Figure 1b was higher than
500 pg/ml (Supplementary Figure S1 online).
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Figure 6. Enhancing FOXP3 stability by low-concentration CCL3 attributed, at least partly, to the prevention of cytoplasmic Sin1 nuclear translocation
by PKC pathway. (a) Akt1/CCR5/Sin1/FOXP3 cells were starved overnight and then treated with Ro-31-8220 of indicated concentrations for 15 min after
pretreatment of CCL3 (0.5 ng/ml) for two hours. Cytoplasmic and nuclear lysates were extracted to analyze Sin1 levels. Nuclear translocation of Sin1 caused
by Ro-31-8220 led to increased nuclear PKB/Akt phosphorylation (S473) and decreased nuclear FOXP3 levels. One representative experiment of three is shown.
(b) Akt1/CCR5/Sin1/FOXP3-RFP were used to analyze the nuclear translocation of cytoplasmic Sin1 caused by Ro-31-8220 using immunofluorescence. Scale
bar¼ 20mm. One representative experiment of three is shown.
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PKB/Akt plays critical roles in cell activities and functions.
It comprises three mammalian isoforms (PKBa/ Akt1, PKB
b/Akt2, PKB g/Akt3) that are derived from distinct genes.
Different functional roles of PKB/Akt isoforms and isoform-
specific signaling contributes to the diversity of PKB/Akt
activities (Gonzalez and McGraw, 2009). Here we
demonstrated that the degradation of FOXP3 promoted by
high-concentration CCL3 mainly depended on its upregulation
of PKBa/Akt1 S473 phosphorylation. Our result was con-
cordant with Crellin’s demonstration that CD4þCD25þ
Tregs displayed a consistent constraint in S473 phospho-
rylation of PKB/Akt. Reduced activity of this pathway was
necessary for the suppressive function of CD4þCD25þTregs
(Crellin et al., 2007). S473 phosphorylation regulates PKB/Akt
kinase activity and substrate specificity (Jacinto et al., 2006).
mTORC2 has been demonstrated to functionally act as the
main kinase complex phosphorylating PKB/Akt at Serine 473
and the PKC pathway (Lee et al., 2010). Within mTORC2,
Sin1 is required for mTORC2 kinase activity (Yang et al.,
2006). Chang et al. demonstrated the necessary role of Sin1 in
Treg development. Sin1 deficiency resulted in an increased
proportion of FOXP3þ Tregs in the thymus (Chang et al.,
2012). In this study we demonstrated Sin1 played a vital role
in the degradation of FOXP3 via activation of S473
phosphorylation in PKB/Akt pathway by high-concentration
CCL3. On the other hand, we found that maintenance of
FOXP3 stability by low-concentration CCL3 required the
maintenance of the PKC pathway and the restriction of the
PKB/Akt pathway. It was also suggested that there should be
some cross-talk between PKC and PKB/Akt pathways
concerning the regulation of FOXP3 stability. It has been
reported that mTORC2 functions in cytoplasmic/endoplasmic
reticulum/nuclear compartments. Cytoplasmic translocation of
nuclear sin1 was associated with the inhibition of the mTORC2
assembly and its function (Rosner and Hengstschla¨ger, 2008;
Boulbe´s et al., 2011). Prolonged rapamycin treatment led to
the downregulation of mTORC2 function by complete
dephosphorylating of Sin1 and its cytoplasmic translocation
from nuclei (Rosner and Hengstschla¨ger, 2008). In the present
study, we demonstrate that Sin1 was the main signal node
functioning downstream of CCL3 in the PKB/Akt and PKC
pathways. This is consistent with published results (Ikenoue
et al., 2008), demonstrating that, in Sin1-/- cells, PKC protein
levels and its phosphorylation were dramatically decreased.
Moreover, PKC kinase activity and substrate phosphorylation
were also impaired in Sin1-/- cells. In our study, we showed
that, under low-concentration CCL3, the high level of FOXP3
and Sin1’s retention in cytoplasm were maintained by the PKC
pathway, because cytoplasmic Sin1 translocated into nuclei
under the condition of a decreased PKC pathway caused
by Ro-31-8220. This nuclear translocation of Sin1 led to
decreased FOXP3 levels. These data demonstrate that
maintenance of FOXP3 stability by low-concentration CCL3
attributed, at least partly, to the prevention of cytoplasmic Sin1
nuclear translocation by the PKC pathway.
Previous substantial studies have demonstrated the negative
roles of PKB/Akt-mTORC1 pathways on the transcription
levels of FOXP3 mRNA (Haxhinasto et al., 2008; Sauer
et al., 2008; Harada et al., 2010; Merkenschlager and von
Boehmer, 2010). Recently researchers found that FOXP3 was
not as stable as has been thought. Under proinflammatory
conditions, FOXP3þTregs could readily differentiate into
inflammation-associated Th17 cells (Sharma et al., 2009;
Zhou et al., 2009; Bovenschen et al., 2011; Lin et al., 2011;
Soler and McCormick, 2011). Herein we provide evidence
that chemokine CCL3, strongly induced by microorganism
infections including streptococcus, was one of the vital links
between infections and FOXP3 stability in the psoriatic
microenvironment. CCL3 manipulated FOXP3 stability in a
concentration-dependent bidirectional manner. Our results
suggested vital roles for the CCL3-mTORC2-isoform Akt1
S473 phosphorylation axis in FOXP3þTregs and the
development of psoriasis. Our study provides evidence to
support the dual negative effects of the PKB/Akt pathway on
FOXP3þ Treg cells.
Finally, it should be pointed out that CCL3 might not be the
sole chemokine triggering the disorder of the immune micro-
environment in psoriasis. A recent study showed chemokine
CCL4/CCL4L (CCL4-like) copy number and secretion were
positively correlated with psoriasis severity (Pedrosa et al.,
2011). Considering high homology of CCL4/CCL4L with CCL3
and their interaction (Ren et al., 2010; Supplementary
Figure S4 online), CCL4/CCL4L might also be involved in
FOXP3 stability regulation in psoriasis, which needs further
investigation. Secondly, we performed ubiquitination reac-
tions of FOXP3 with fibroblast cell lines, not with isolated
CD4þCD25þT cells according to the failure in preliminary
experiments due to the low FOXP3þ percentage in PBMC.
Fibroblast cells have been demonstrated to take part in the
inflammatory reaction in psoriasis (Glowacka et al., 2010;
Schirmer et al., 2010). Although not typical immune cells,
fibroblast cells have been demonstrated to express FOXP3 and
immune cytokines/receptors, including CCL3 and CCR5, upon
stimulation (Konishi et al., 1996; Maurer and von Stebut,
2004; Zhu Shen et al., submitted). However, it is a fact that
there should be some differences between these two cell types
according to differences in their structures. Thus, FOXP3’s
ubiquitination and degradation by CCL3 which was performed
based on fibroblast cell lines should be further confirmed with
FOXP3þ T cells.
MATERIALS AND METHODS
Patients and specimens
Eleven patients of AGP with disease course of no less than one week,
15 patients of CPP younger than 40 year-old, and 12 young healthy
blood donors were enrolled in this study (Supplementary Material
online). This study was approved by the Institutional Review Board of
Daping Hospital, and it adhered to the Declaration of Helsinki
guidelines. Written, informed consent was obtained from each subject.
PBMCs and CD4þCD25þ T cell isolation
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll
density gradient centrifugation. CD4þCD25þ T cells were purified
from PBMCs by magnetic-bead-based separation according to the
manufacturer’s instructions (CD4þCD25þ Regulatory T Cell Isola-
tion Kit, Supplementary Material online).
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Western blot and Immunoprecipitation
Cells were washed three times with PBS before being scraped into an
Eppendorf tube. Western blot and immunoprecipitation were per-
formed by standard molecular biological protocol with some mod-
ifications (Supplementary Material online).
ELISA
The serum from AGP and CPP were collected. Quantification of serum
CCL3 was performed using Quantikine ELISA kits (R&D Systems,
Minneapolis, MN) according to the manufacturer’s instructions.
FOXP3 immunohistochemical staining
FOXP3 expression in AGP and CPP was analyzed immunohisto-
chemically using anti-human FOXP3 monoclonal antibody as pre-
viously described (Chen et al., 2008) (Supplementary Material online).
Fibroblast cell line establishment
Cell lines were established on 3T3 fibroblast cells and immortalized
lung fibroblast cells from Akt1 fl/flAkt2 /Akt3 / mice (a gift from
Prof. Philip N. Tsichlis, Supplementary Material online).
Cycloheximide chase analysis
After starvation overnight, cells were treated with cyclohexomide (50
mg/mL, Sigma, St Louis, MO) for indicated time. FOXP3 protein was
immunoprecipitated with anti-HA antibody and analyzed by western
blot with anti-FOXP3 antibody.
Cell stimulation assay
After starvation for 6 h (CD4þCD25þ T cells) or overnight (fibroblasts
with 80% confluence), the following stimulations of indicated con-
centration and their vehicle control were added separately or
combination for indicated time: CCL3 and IGF-1 (R&D Systems,
Minneapolis, MN) dissolved in PBS, Maraviroc (a gift from Prof. Joseph
G. Sodroski), MK2206 (Merck, Germany), Ro-31-8220 (Calbiochem,
Germany), and PMA (Sigma, St Louis, MO) dissolved in DMSO.
Immunofluorescence staining
Cells were grown on sterile glass cover slips overnight. After stimula-
tion, cells were washed with PBS extensively and immunofluorescence
staining was performed as described (Supplementary Material).
Statistical analysis
Analysis for statistically significant differences was performed
with Student’s t test, Chi-square test, and Spearman correlation test.
P-values o0.05 were considered significant.
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